aMoon Fund

Ibex Medical Analytics Ltd, based in Tel Aviv, Israel, specializes in developing AI-based diagnostic systems for cancer pathology. The company's flagship product, the Ibex Second Read system, works alongside human pathologists to analyze cases, identifying discrepancies in diagnoses. This innovative technology harnesses artificial intelligence, data science, and machine learning to analyze digitized glass slides and electronic medical records, revealing critical patterns that enhance clinical decision-making. By streamlining pathology workflows, Ibex aims to provide rapid, objective, and accurate diagnoses, ultimately improving patient outcomes and quality of life. The company comprises a multidisciplinary team of entrepreneurs, data scientists, software engineers, and medical experts dedicated to advancing cancer care through AI applications in diagnostics.

Nectin Therapeutics Ltd., founded in 2017 and based in Jerusalem, Israel, specializes in the development of monoclonal antibodies targeting members of the Nectin family of receptors and ligands. These antibodies are designed to address immune checkpoint mechanisms that play a crucial role in cancer immunotherapy. By focusing on both solid and hematological malignancies, Nectin Therapeutics aims to create therapies that can overcome the inhibitory pathways utilized by tumors, thereby enhancing the ability of immune cells to eradicate cancer cells. The company's innovative approach seeks to improve patient outcomes in cancer treatment.

Ibex Medical Analytics Ltd, based in Tel Aviv, Israel, specializes in developing AI-based diagnostic systems for cancer pathology. The company's flagship product, the Ibex Second Read system, works alongside human pathologists to analyze cases, identifying discrepancies in diagnoses. This innovative technology harnesses artificial intelligence, data science, and machine learning to analyze digitized glass slides and electronic medical records, revealing critical patterns that enhance clinical decision-making. By streamlining pathology workflows, Ibex aims to provide rapid, objective, and accurate diagnoses, ultimately improving patient outcomes and quality of life. The company comprises a multidisciplinary team of entrepreneurs, data scientists, software engineers, and medical experts dedicated to advancing cancer care through AI applications in diagnostics.

MDClone Ltd. is a company that specializes in developing software for analyzing medical records while ensuring the privacy of patient data. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients, which allows researchers to study disease behavior, healthcare practices, and treatment outcomes without exposing actual patient information. The MDClone ADAMS Platform provides a self-service data analytics environment that facilitates exploration, discovery, and collaboration across healthcare systems, both nationally and internationally. This innovative approach addresses common barriers in healthcare by enabling users to organize and access data efficiently, thereby improving operations and enhancing patient outcomes. MDClone serves various clients in the healthcare sector, including major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

DayTwo Ltd. is a precision nutrition company headquartered in Tel Aviv-Yafo, Israel, that focuses on leveraging gut microbiome insights to improve health outcomes and prevent diseases such as diabetes, prediabetes, obesity, and non-alcoholic fatty liver disease (NAFLD). Founded in 2015, DayTwo employs microbiome sequencing to create personalized dietary recommendations, known as Food Prescriptions™, tailored to individual responses to food. This approach helps manage blood sugar levels, enhance energy, control hunger, and promote weight loss. DayTwo delivers its services through a digital platform and mobile application, enabling users to track their progress and communicate with certified diabetes care specialists and registered dietitians. By emphasizing personalized nutrition based on scientific research, DayTwo aims to empower patients to lead healthier lives through informed dietary choices.

Ibex Medical Analytics Ltd, based in Tel Aviv, Israel, specializes in developing AI-based diagnostic systems for cancer pathology. The company's flagship product, the Ibex Second Read system, works alongside human pathologists to analyze cases, identifying discrepancies in diagnoses. This innovative technology harnesses artificial intelligence, data science, and machine learning to analyze digitized glass slides and electronic medical records, revealing critical patterns that enhance clinical decision-making. By streamlining pathology workflows, Ibex aims to provide rapid, objective, and accurate diagnoses, ultimately improving patient outcomes and quality of life. The company comprises a multidisciplinary team of entrepreneurs, data scientists, software engineers, and medical experts dedicated to advancing cancer care through AI applications in diagnostics.

Nectin Therapeutics Ltd., founded in 2017 and based in Jerusalem, Israel, specializes in the development of monoclonal antibodies targeting members of the Nectin family of receptors and ligands. These antibodies are designed to address immune checkpoint mechanisms that play a crucial role in cancer immunotherapy. By focusing on both solid and hematological malignancies, Nectin Therapeutics aims to create therapies that can overcome the inhibitory pathways utilized by tumors, thereby enhancing the ability of immune cells to eradicate cancer cells. The company's innovative approach seeks to improve patient outcomes in cancer treatment.

Curesponse is a diagnostics company based in Tel Aviv-Yafo, Israel, founded in 2017. It specializes in developing a three-dimensional tissue culture system that models cancer growth and drug response. The company's innovative platform allows patients and clinicians to send tumor samples for testing, preserving the cancer tissue's architecture, including its vasculature and immune system. This accurate reflection of cancer growth enables healthcare providers to make more informed decisions about drug therapies tailored to individual patients. By moving beyond traditional genomic predictions to functional responses in living patient cells, Curesponse aims to enhance personalized cancer medicine, improve survival rates, and reduce unnecessary medical interventions.

Igentify Ltd is a company focused on preventive healthcare through genomic products and services, with a particular emphasis on the Jewish and Israeli population. Founded in 2016 and headquartered in Haifa, Israel, Igentify developed FamilyFirst, an expanded carrier screening tool designed to identify genetic conditions. The company operates an end-to-end digital genetic platform that enhances the accessibility and usability of genomic information for clinicians, laboratories, and patients. By streamlining processes such as education on genetic testing, consent collection, and data analysis, Igentify aims to facilitate a more efficient and comprehensive approach to genomic medicine.

MDClone Ltd. is a company that specializes in developing software for analyzing medical records while ensuring the privacy of patient data. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients, which allows researchers to study disease behavior, healthcare practices, and treatment outcomes without exposing actual patient information. The MDClone ADAMS Platform provides a self-service data analytics environment that facilitates exploration, discovery, and collaboration across healthcare systems, both nationally and internationally. This innovative approach addresses common barriers in healthcare by enabling users to organize and access data efficiently, thereby improving operations and enhancing patient outcomes. MDClone serves various clients in the healthcare sector, including major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

DayTwo Ltd. is a precision nutrition company headquartered in Tel Aviv-Yafo, Israel, that focuses on leveraging gut microbiome insights to improve health outcomes and prevent diseases such as diabetes, prediabetes, obesity, and non-alcoholic fatty liver disease (NAFLD). Founded in 2015, DayTwo employs microbiome sequencing to create personalized dietary recommendations, known as Food Prescriptions™, tailored to individual responses to food. This approach helps manage blood sugar levels, enhance energy, control hunger, and promote weight loss. DayTwo delivers its services through a digital platform and mobile application, enabling users to track their progress and communicate with certified diabetes care specialists and registered dietitians. By emphasizing personalized nutrition based on scientific research, DayTwo aims to empower patients to lead healthier lives through informed dietary choices.

Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing small molecule therapeutics for patients with rare and aggressive cancers. Founded in 2017 and based in Rehovot, Israel, the company aims to address genetically defined patient populations by targeting the tumorigenic drivers of cancer. Its lead product candidate, AL101, is an intravenous gamma secretase inhibitor currently undergoing Phase II clinical trials for the treatment of recurrent and metastatic adenoid cystic carcinoma in patients with Notch-activating mutations. Additionally, Ayala is developing AL102, an oral gamma secretase inhibitor, which is in Phase I clinical trials for desmoid tumors and has a collaboration with Novartis to further develop this compound for multiple myeloma. The company's innovative approach combines bioinformatics and next-generation sequencing to deliver targeted therapies to underserved patient populations.

CartiHeal is a medical device company based in Kfar Sava, Israel, specializing in cartilage and bone regeneration. Founded in 2009, the company has developed the Agili-C implant, a cell-free and off-the-shelf solution designed to address focal articular cartilage and osteochondral defects. This innovative implant promotes the regeneration of hyaline cartilage and the underlying subchondral bone without the need for cells or growth factors, making it a significant advancement in the treatment of cartilage injuries. Given the limited natural healing capacity of hyaline cartilage, CartiHeal's technology offers a promising option for patients suffering from cartilage damage, which can lead to severe pain and disability if untreated. The Agili-C implant can be inserted using arthroscopic or minimally invasive techniques, facilitating faster rehabilitation and enhanced recovery outcomes for patients.